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Abstract
Recent evidence has suggested that IL-10-producing effector CD8+ T cells play an important role 
in regulating excessive inflammation during acute viral infections. However, the cellular and 
molecular cues regulating the development of IL-10-producing effector CD8+ T cells are not 
completely defined. Here we show that type I interferons (IFNs) are required for the development 
of IL-10-producing effector CD8+ T cells during influenza virus infection. We find that type I 
IFNs can enhance IL-27 production by lung antigen presenting cells, thereby facilitating IL-10-
producing CD8+ T cell development through a CD8+ T cell non-autonomous way. Surprisingly, 
we also demonstrate that direct type I IFN signaling in CD8+ T cells is required for the maximal 
generation of IL-10-producing CD8+ T cells. Type I IFN signaling in CD8+ T cells, in cooperation 
with IL-27 and IL-2 signaling, promotes and sustains the expression of IRF4 and Blimp-1, two 
transcription factors required for the production of IL-10 by effector CD8+ T cells. Our data have 
revealed a critical role of the innate antiviral effector cytokines in regulating the production of a 
regulatory cytokine by effector CD8+ T cells during respiratory virus infection. The potential 
implications of these findings for influenza virus infection are also discussed.
Introduction
CD8+ T cells are the key to clear infectious virus, intracellular bacteria and transformed 
cells. Upon antigenic encountering in the secondary lymphoid organs, naïve CD8+ T cells 
undergo stepwise stages of responses including activation, expansion and differentiation into 
effector CD8+ T cells (i.e. cytotoxic T lymphocytes) (1, 2). Effector CD8+ T cells acquire 
tissue tropic chemotactic receptors such as CCR5 and CXCR3 while simultaneously 
downregulate lymphoid tissue homing receptors such as CCR7 (1, 2), which allow them to 
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infiltrate peripheral tissues to clear pathogen-infected or transformed cells. In the tissue, 
effector CD8+ T cells use multiple mechanisms to combat invading enemies. Most 
prominently, effector CD8+ T cells express key cytolytic molecules including granzymes, 
perforin and death receptor ligands and are able to clear virus infected cells or transformed 
cells through contact dependent mechanisms. In addition, effector CD8+ T cells also express 
multiple anti-viral and anti-tumor pro-inflammatory cytokines, such as IFN-γ and TNF-α, to 
inhibit viral replication and kill tumor cells. Notably, these direct and indirect antiviral and 
tumor activities of effector CD8+ T cells, if unchecked, also can cause severe inflammation 
and tissue destruction (1, 3–5).
Recently, we and others have demonstrated that effector CD8+ T cells are able to produce 
the regulatory cytokine IL-10 in the lung and brain following acute viral infections (6–11). 
The production of IL-10 by effector CD8+ T cells is important in counterbalancing 
exuberant inflammation as the blockade of IL-10 following infection has resulted in 
exaggerated inflammation and severe host diseases during influenza, respiratory syncytial 
virus (RSV) and coronavirus infections (7–12). Furthermore, we showed that IL-2 co-
operates with innate cell-derived IL-27 to up-regulate IL-10 production by CD8+ T cells 
specifically in the lung through the transcription factor Blimp-1-dependent mechanisms (6). 
However, the current understanding on the cellular and molecular mechanisms regulating the 
development of IL-10-producing effector CD8+ T cells remain incompletely defined.
Type I IFNs are major anti-viral effector cytokines that have critical roles in shaping both 
innate and adaptive defense against viral infections. Initially discovered as the 
proinflammatory “signal 3” cytokines, type I IFNs were shown to promote CD8+ T cell 
expansion and effector differentiation during bacterial and viral infections (13, 14). 
Moreover, type I IFN signaling in CD8+ T cells can protect CD8+ T cell from NK cell-
mediated deletion during chronic virus infection (15, 16). Besides their role in enhancing 
anti-viral immune responses, type I IFNs signals also promotes IL-10 and PD-L1 
production/expression and suppress effective CTL responses during chronic LCMV 
infection (17, 18), suggesting that type I IFN signaling possesses immune-regulatory 
functions. Similarly, recent evidence has demonstrated that type I IFNs are required for 
IL-10 production during influenza infection (19, 20). Arimori et al showed that IFNAR1-
deficient mice exhibited diminished IL-10 levels in the lung, enhanced pro-inflammatory 
cytokine production and increased host mortality following influenza virus infection (20). 
However, how type I IFN signaling promotes IL-10 production during influenza infection is 
currently unknown. Furthermore, given that T cells, particularly effector CD8+ T cells, are a 
major cellular source of IL-10 during influenza infection, it is important to determine 
whether and how type I IFN signaling affects IL-10 production of T cells.
In this report, we have examined the role of type I IFN signaling in the induction of IL-10-
producing T cells during influenza infection. We found that type I IFN signaling is critically 
important in driving IL-10 production by effector CD8+ T cells, but only plays modest role 
in promoting IL-10 production by CD4 T cells during influenza infection. We found that 
type I IFN signaling promotes IL-27 production by APCs to indirectly facilitate CD8+ T cell 
IL-10 production in a CD8+ T cell non-autonomous fashion. Interestingly, we found that 
direct type I IFN signaling in CD8+ T cells is also critical for the maximal generation of 
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IL-10-producing effector CD8+ T cells during influenza infection. Mechanistically, type I 
IFN signaling, in cooperation with IL-27 and IL-2 signaling, promotes and sustains the 
expression of Blimp-1 and IRF4, two transcription factors required for the production of 
IL-10 by effector CD8+ T cells. Our data have revealed the underlying molecular 
mechanisms by which innate antiviral effector cytokines regulates the production of a 
regulatory cytokine by effector CD8+ T cells during respiratory virus infection.
Materials and Methods
Mouse and infection
WT C57/BL6 mice were purchased from the Jackson Laboratory, Blimp-1 control 
(Prdm1fl/fl), CD4-Cre transgenic, CD8-cre transgenic, IRF4 control (Irf4fl/fl) and CD45.1 
congenic mice were originally from the Jackson Laboratory and bred in house. T cell-
specific Blimp-1 conditional knockout (cKO) mice were generated through breeding CD4-
cre to Prdm1fl/fl mice. CD8 T cell-specific IRF4 cKO mice were generated through breeding 
CD8-cre to Irf4fl/fl mice. IFNAR1-deficient (Ifnar1−/−) mice were originally from Dr. U. 
Deshmukh at the University of Virginia; Vert-X mice were originally from Dr. C. Karp from 
Cincinnati Children’s Hospital; STAT2-deficient (Stat2−/−) mice were originally from Dr. C. 
Schindler at the Columbia University. All mice were housed in a specific pathogen-free 
environment and all animal experiments were performed in accordance with protocols 
approved by the University of Virginia Animal Care and Use Committee (ACUC) or Indiana 
University Institutional Animal Care and Use Committee (IACUC). For influenza virus 
infection, mice were anesthetized first and then intranasally infected with Influenza A/
PR8/34 strain (~150 pfu/mouse in serum-free IMDM media (Gibco) or PBS) as previously 
reported (8).
Quantitative RT-PCR
Lung single cell suspensions were prepared as previously described (6, 21). T cells were 
purified through positive selection via MACS-beads (Miltenyi Biotech) from pooled 2 – 3 
lungs per group. mRNA from in vivo purified cells or in vitro cultured cells as indicated was 
isolated with RNeasy kit (Qiagen) or total RNA isolation kit (Sigma Aldrich) and treated 
with DNase I (Invitrogen). Random primers (Invitrogen) and Superscript II (Invitrogen) 
were used to synthesize first-strand cDNAs from equivalent amounts of RNA from each 
sample. RT-PCR was performed with SYBR Green PCR Master Mix (Applied Biosystems). 
Data were generated with the comparative threshold cycle (Delta CT) method by 
normalizing to hypoxanthine phosphoribosyltransferase (HPRT). Sequences of primers used 
in the studies are available on request.
In vitro DC/T cell co-culture
BMDC were generated as described (22). CD8+ T cells were isolated from spleen and lymph 
nodes of indicated mice through MACS-beads (Miltenyi Biotech). BMDC and T cell co-
culture was performed as previously described (6). Briefly, we mixed DC with CD8+ T cells 
at the ratio of 1 DC : 10 T cells in round-bottom 96 wells (5 × 104 T cells/well) in the 
presence of 0.1 µg/ml α-CD3. The conditions of the culture are indicated in the text. For 
RNA isolation and RT-PCR, T cells were harvested at day 3 of culture. For IFN-γ and IL-10 
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staining, T cells were harvested at day 4 of the culture and restimulated with PMA (100 
ng/ml, Sigma) or inomycin (1 µg/ml, Sigma) in the presence of Golgi-Stop (1 µl/ml, BD 
Biosciences) for 4 hours. Intracellular cytokine staining (ICS) was performed as we 
previously reported (6). To measure T cell cytokine production by ELISA, day 4 cultured T 
cells were restimulated with plate bound α-CD3 (1 µg/ml) for overnight. Supernatants were 
then measured by ELISA as previously described (6). The concentrations of the cytokines 
used in the culture are as following: recombinant human IL-2 (300 U/ml); mouse IL-27 
(Biolegend), 10 ng/ml and IFN-αA (R&D) 250 U/ml respectively.
Antigenic stimulation of lung effector T cells
On day 6–7 of WT BMDC culture, BMDC were harvested and infected with influenza virus 
at approximated 100 M.O.I. for 6 h. Then BMDC were counted and mixed with total lung 
cells isolated from WT and transgenic mice as indicated in the text at a 1.5 to 1 ratio in the 
presence of Golgi-Stop (BD Biosciences, 1µl/ml) and hIL-2 (40 U/ml) for additional 6 h. 
The surface staining of cell surface markers, intracellular staining of cytokines was 
performed as described (8).
Generation of mixed bone marrow chimeras
To generate mixed bone marrow chimera, we lethally irradiated (1100 Rads) WT mice and 
then i.v. injected ~ 4 million 1:1 mixed BM cells from WT (CD45.1+) or CD45.2+ IFNAR1-
deficient BM. After 12 week reconstitution, the chimeric mice were then infected with 
influenza A/PR8.
Broncho-alveolar lavage (BALF) cytokine determination
BALF was obtained by flushing the airway 3 – 4 times with a single use of 600 µl sterile 
PBS as previous described (8). Cells in BALF were spun down and supernatants were 
collected for multi-plex analysis (Millipore) according to the manufacturer manuals.
Cell sorting
Lung single cell suspensions were prepared from uninfected or infected mice (day 5 p.i.). 
Cells were stained with CD45, F4/80, CD11C, MHCII, CD11b and Ly6G. Lung eipthelia/
stroma cells (CD45−), Neutrophils (CD11b+ Ly6G+), DCs (CD11chi MHCIIhi Ly6G−) and 
macrophages (F4/80+ MHCII+ Ly6G−) were sorted based on their surface marker expression 
described above.
FACS analysis
All FACS Abs were purchased from Biolegend, BD Biosciences or eBioscience. Cells were 
acquired through FACS-Calibur, FACS-Canto or LSR II (BD Biosciences). Data were then 
analyzed by FlowJo software (Treestar).
Statistical analysis
Data are mean ± s.e.m. Paired or unpaired two-tailed Student’s t-test was used. P values < 
0.05 is considered significant.
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Online supplementary figures
Four supplementary figures can be found with this article online.
Results
IFNAR1 and STAT2 are required for the development of IL-10-producing effector CD8+ T 
cells during influenza infection
To determine the role of type I IFNs in the development of IL-10-producing effector CD8+ T 
cells, we infected WT and IFNAR1-deficient mice with influenza. At day 7 post infection (at 
the time when maximal IL-10 was made in vivo (6, 8), we stimulated lung T cells with 
influenza-infected WT bone marrow-derived dendritic cells (BMDCs) and measured IL-10 
and IFN-γ production by T cells following stimulation as we previously reported (6, 8). We 
found that IFNAR1 deficiency modestly affected IFN-γ production by CD8+ T cells, but 
dramatically diminished IL-10 production by CD8+ T cells (Figure 1A). We then normalized 
IL-10+ CD8+ T cells to IFN-γ+ CD8+ T cells to determine the relative abundance of IL-10-
producing cells in IFN-γ producing antigen specific CD8 T cells. We found that IFNAR1 
deficiency significantly abrogated IL-10-producing CD8+ T cells within the antigen-specific 
CD8+ T cell population (Figure 1B). IFNAR1 deficiency also decreased the per cell 
production of IL-10 by effector CD8+ T cells as the mean fluorescence intensity (MFI) of 
IL-10 in IL-10+ cells diminished in the absence of IFNAR1 (Figure S1A). In addition, 
IFNAR1 deficiency diminished IL-10-producing CD4+ T cells (Figure 1C), although the 
relative abundance of IL-10-producing CD4+ T cells in antigen-specific IFN-γ+ CD4 T cells 
only modestly diminished in the absence of IFNAR1 (Figure 1D). Consistent with their 
diminished levels of IL-10-producing CD8+ and CD4+ T cells, IFNAR1-deficient mice 
exhibited diminished airway IL-10 levels and increased airway IFN-γ levels in vivo during 
influenza infection (Figure 1E and F), consistent with the recent findings that type I IFN 
signaling is required for IL-10 but not IFN-γ production in vivo during influenza infection 
(19, 20). Following type I IFNs engagement, IFNAR initiates downstream events to form a 
signaling complex consisting of STAT1/STAT2/IRF9, which mediate the major functions of 
type I IFNs (23, 24). We therefore examined whether STAT2 is required for the generation 
of IL-10-producing CD8+ T cells in vivo during influenza infection. We found that STAT2 
deficiency significantly diminished IL-10-producing CD8+ T cells in the lung (Figure 1G, 
H). STAT2 deficiency also significantly decreased IL-10 MFI in IL-10+ CD8+ effector T 
cells (Figure S1B). Taken together, these data suggested that STAT2-dependent IFNAR1 
signaling is required for the generation of IL-10-producing effector CD8+ T cells during 
influenza infection.
To further support this idea, we crossed IFNAR1-deficient mice to IL-10-IRES-eGFP 
reporter mice (Vert-X), as these mice faithfully report IL-10 expression by T and other cells 
without the need of in vitro restimulation (25). We infected IFNAR1-deficient Vert-X mice 
with influenza and then examined in vivo IL-10 production through the reporter eGFP 
expression on T cells at day 7 post infection. We found that, compared to those of IFNAR1-
sufficient Vert-X mice, CD8+ T cells from IFNAR1-deficient mice exhibited diminished 
percentages of IL-10/eGFP+ cells (Figure 2A, B) and a lower per cell levels of IL-10/eGFP 
(Figure 2C), consistent with the idea that IFNAR1 signaling is required for the potent 
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induction of IL-10-producing CD8+ T cells. We also examined IL-10/eGFP expression by 
influenza-specific PA224 tetramer+ CD8+ T cells and found that the deficiency of IFNAR1 
resulted in decreased percentages of IL-10/eGFP+ cells within PA224+ CD8+ T cell 
population and diminished IL-10/eGFP MFI (Figure 2D – F). The deficiency of IFNAR1 did 
not significantly decrease IL-10/eGFP expression by CD4 T cells (Figure 2G, H). Taken 
together, these data suggested that IFNAR1 signaling is preferentially required for the 
development of IL-10 expressing CD8+ T cells.
Type I IFN signaling is required for the maximal production of IL-27
We recently have demonstrated that IL-27 is vital for the development of IL-10-producing 
effector CD8+ T cells during influenza infection. Type I IFNs have been shown to stimulate 
IL-27 production by antigen presenting cells (26). We found that antigen presenting cells 
(APCs, including macrophages, DCs and neutrophils) are the main sources of IL-27 
expression (particularly p28 subunit) in the lung at day 5 post influenza infection, at the time 
when effector T cells begin to migrate to the lungs and upregulate IL-10 expression there 
(Figure 3A). Consistent with the previous findings, we found that type I IFNs were able to 
induce the expression of IL-27 in dendritic cells, macrophages and neutrophils (Figure S2), 
the main antigen presenting cell types in the infected lungs when CD8+ T cells start to 
produce IL-10 (27, 28). Therefore, we reasoned that type I IFNs induce IL-27 production, 
thereby supporting IL-10 production by CD8+ T cells. To address this hypothesis, we 
examined the expression of IL-27 subunits in the draining mediastinal lymph nodes (MLN) 
and the lungs (6, 8). We found that, compared to those of WT mice, Ebi3 and p28 expression 
in the lung of IFNAR1-deficient mice was significantly decreased (Figure 3B). Furthermore, 
airway IL-27 p28 protein levels were also diminished in IFNAR1-deficient mice following 
influenza infection (Figure 3C). Together, these data suggest that type I IFN signaling is 
required for the optimal production of the IL-10 inducing cytokine, IL-27, during influenza 
infection.
Cell-intrinsic IFNAR1 signaling is required for the maximal development of IL-10-producing 
effector CD8+ T cells
Type I IFNs are important “signal 3” cytokines that can directly drive CD8+ T cell 
differentiation (13, 14). We next want to examine whether direct type I IFN signaling in 
CD8+ T cells may influence IL-10 production beyond their cell non-autonomous effects in 
promoting IL-10 production by CD8+ T cells through the induction of IL-27 production. To 
do so, we lethally irradiated WT mice and then reconstituted the mice with 1:1 mixed CD45 
mis-matched WT and IFNAR1-deficient bone marrow cells (Figure 4A). 12 weeks after 
reconstitution, we infected the chimeric mice with influenza and found that the T cell 
compartments in the lungs of the infected mice were successfully reconstituted with both 
WT or Ifnar1−/− cells (Figure S3A). We then checked IL-10 and IFN-γ production following 
in vitro restimulation of T cells. We found that IL-10 production by IFNAR1-deficient CD8+ 
T cells is significantly lower than that of WT CD8+ T cells even within the same hosts 
(Figure 4B, C). Furthermore, the IL-10 MFI is also significantly lower in IFNAR1-deficient 
CD8+ T cells than that of WT CD8+ T cells (Figure 4D). In contrast, IL-10 production by 
CD4+ T cells is comparable between WT and IFNAR1 deficient CD4+ T cells (Figure 4E 
and Figure S3B). Taken together, these data suggest that CD8+ T cell-autonomous type I 
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IFN signaling is also essential for the maximal development of IL-10-producing effector 
CD8+ T cells, but not IL-10-producing CD4+ T cells.
Type I IFNs further promote IL-10 production by CD8+ T cells in the presence of IL-2 plus 
IL-27
To begin to examine the underlying cellular and molecular mechanisms by which type I IFN 
signaling promotes IL-10 production by CD8+ T cells, we employed our previously reported 
CD8+ T cell culture system (6). To this end, we cultured WT CD8+ T cells in the absence or 
presence of IFN-α, IL-2 and IL-27 (IL-2/IL-27), or IFN-α plus IL-2/27 (IFN-α/IL-2/IL-27). 
We found that the inclusion of IFN-α alone in the culture minimally induced the 
development of IL-10-producing CD8+ T cells in vitro (Figure 5A). However, IFN-α helped 
the development of IL-10-producing CD8+ T cells in the presence of IL-2 and IL-27 (Figure 
5A, B), which were reported to induce IL-10-producing effector CD8+ T cells (6). IFN-α 
also promoted IL-10 mRNA expression in CD8+ T cells in the presence of IL-2 and IL-27 
(Figure 5C). In addition, although IFN-α alone minimally induced IL-10 secretion by 
effector CD8+ T cells, it greatly enhanced IL-10 secretion by CD8+ T cells in the presence 
of IL-2 plus IL-27 (Figure 5D). Taken together, these data suggested that type I IFNs co-
operate with IL-2 and IL-27 to promote IL-10 production by CD8+ T cells.
Blimp-1 and IRF4 are required for the development of IL-10-producing effector CD8+ T cells 
induced by type I IFNs plus IL-2 and IL-27
We next wished to determine the molecular mechanisms by which type I IFNs co-operate 
with IL-2 and IL-27 to promote the development of IL-10-producing CD8+ T cells. We have 
shown previously that Blimp-1 is required for the development of IL-10-producing CD8+ T 
cells in vitro and in vivo during influenza infection (6). We now observed that type I IFNs 
cooperated with IL-2 and IL-27 to induce the expression of Blimp-1 in CD8+ T cells (Figure 
6A, B). To determine whether Blimp-1 is required for the induction of IL-10-producing 
CD8+ T cells in vitro, we cultured WT or Blimp-1-deficient CD8+ T cells in the absence or 
presence of IFN-α, IL-2/IL-27 or IFN-α/IL-2/IL-27. We found that while IFN-α/IL-2/IL-27 
induced abundant IL-10-producing CD8+ T cells within WT CD8+ T cells, these cytokine 
failed to stimulate IL-10 production by Blimp-1-deficient CD8+ T cells (Figure 6C). 
Furthermore, Blimp-1 was also required for the secretion of IL-10 by CD8+ T cells (Figure 
6D). Thus, these data suggest that Blimp-1 is required for the production of IL-10 by CD8+ 
T cells upon type I IFN signaling, consistent with the our previous findings that Blimp-1 is 
essential for the development of IL-10-producing CD8+ T cells in vivo during influenza 
infection (6). We recently reported that IRF4 controls Blimp-1 expression in CD8+ T cells 
(29). IRF4 was also shown to regulate IL-10 production by effector CD4+ T cells and 
Foxp3+ regulatory CD4+ T cells (30, 31). We therefore examined whether type I IFNs 
signaling promoted IRF4 expression. We found that IFN-α was able to co-operate with IL-2/
IL-27 to promote and sustain IRF4 expression in CD8+ T cells (Figure 6E and Figure S4). 
Furthermore, we found that, following the treatment of IFN-α/IL-2/IL-27, IRF4 expression 
in CD8+ T cells was required for the production of IL-10 by CD8+ T cells (Figure 6F, G). To 
determine whether IRF4 is required for the induction of IL-10-producing CD8+ T cells in 
vivo, we infected CD8+ T cell-specific IRF4-deficient mice (IRF4 cKO) with influenza and 
examined IL-10 and IFN-γ production following in vitro restimulation. Consistent with our 
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previous data (29), selective IRF4-deficiency in CD8+ T cells diminished IFN-γ production 
by CD8+ T cells, suggesting IRF4 is required for the development of anti-viral effector 
CD8+ T cells (Figure 6H). When IL-10-producing CD8+ T cells were normalized to IFN-γ 
producing effector CD8+ T cell population, we found that IL-10 production was diminished 
in effector CD8+ T cells in the absence of IRF4 (Figure 6I), suggesting that IRF4 is vital for 
the production of IL-10 by effector CD8+ T cells in vivo.
Discussion
In this report, we have investigated the role of type I IFN signaling in regulating the 
development of IL-10-producing effector CD8+ T cells during influenza infection. In 
accordance with previous observations (20), we found that IFNAR1-deficient mice exhibited 
diminished IL-10 production during influenza virus infection. We further showed that the 
effect of IFNAR1 deficiency on IL-10 production was more pronounced on effector CD8+ T 
cells rather than effector CD4+ T cells. We have also defined the downstream cellular and 
molecular mechanisms by which type I IFNs control the development of IL-10-producing 
effector CD8+ T cells during influenza virus infection. We found that both indirect and direct 
effects of type I IFN signaling in CD8+ T cells were required for the optimal induction of 
IL-10-producing CD8+ T cells during influenza infection (Figure 6I).
Type I IFNs are major antiviral effector cytokines that play important roles in restricting the 
replication and dissemination of respiratory viruses in vitro and in vivo (24). Besides their 
direct anti-viral functions, type I IFNs are well known to regulate the development of innate 
and adaptive immunity during respiratory virus infections (32, 33). Early type I IFN 
signaling was important in the production of inflammatory cytokines during influenza 
infection (34, 35). Furthermore, type I IFN signaling plays a critical role in regulating the 
development anti-viral CD4+ and CD8+ cytotoxic T lymphocytes during influenza infection 
(21). Consistent with their role in promoting inflammation and immunity, overproduction of 
type I IFNs contributed significantly to the pathogenesis of influenza virus and mouse 
adapted coronavirus infection (36–38). On the other hand, our data here and results from 
Arimori et al have also suggested that type I IFNs could have regulatory role by restricting 
exuberant inflammatory responses through the induction of the anti-inflammatory cytokine 
IL-10 (20). Indeed, IFNAR1-deficient mice showed an exuberant host inflammatory 
response and IL-10 administration could ameliorate excessive lethal inflammation and 
associated mortality following influenza infection in IFNAR1-deficient mice (20). Such a 
regulatory role of type I IFN signaling in inflammation and immunity has been documented 
during chronic viral infections (17, 18). Thus, type I IFNs could display differing roles in 
regulating the development of inflammatory responses and immunity following viral 
infections, and their exact function in regulating inflammation and immunity would be 
dependent on the infectious organism as well as the timing and levels of the production of 
these pluripotent anti-viral cytokines.
In a similar way, IL-10 exerts its function in a timing-dependent fashion during influenza 
infection. Early production of IL-10 during influenza infection could hamper the activation 
of antiviral innate and adaptive immunity as evidenced by the enhanced resistance to 
influenza virus infection in IL-10-deficient mice (39–41). Conversely, the production of 
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IL-10 at the time of effector T cell infiltration into the lung (i.e. day 5 and thereafter) could 
suppress the development of lethal pulmonary inflammation during influenza infection (8, 
41). Similar beneficial effects of T-cell derived IL-10 have also been reported during 
respiratory syncytial virus and coronavirus infection (7, 9–11). Currently, the role of type I 
IFNs in regulating IL-10 production by human CD8+ T cells has not been investigated. 
However, a recent clinical study has established that both type I IFNs and IL-10 were 
elevated in patients with severe influenza virus infection (42). These data suggested that type 
I IFNs might facilitate IL-10 production by effector T cells during human influenza 
infection. Whether IL-10 production is beneficial to the host by keeping inflammation under 
control or is detrimental to the host by suppressing anti-viral immunity in these patients 
warrants further investigation. However, understanding the timing and dose-dependent 
regulating of pulmonary inflammation and immunity by type I IFNs and IL-10 will be 
insightful for developing novel therapeutic strategies aiming to dampen excessive respiratory 
inflammation and diseases during severe influenza infection.
Type I IFNs have been shown to promote macrophage IL-10 production through the 
induction of the cytokine IL-27 (26). Similarly, we found that type I IFNs could stimulate 
IL-27 expression in major lung antigen presenting cells during influenza virus infection, 
including macrophages, dendritic cells and neutrophils. Furthermore, IL-27 levels were 
significantly diminished in the respiratory tract in the absence of type I IFN signaling. Thus, 
type I IFNs could promote IL-10 production by CD8+ T cells through its indirect effects on 
regulating IL-27 levels in vivo. Surprisingly, through the mixed bone marrow chimera 
experiments, we have also established that direct type I IFN signaling is important in IL-10 
production by CD8+ T cells during influenza infection. Currently, the relative contribution of 
the indirect and direct effects of type I IFN signaling in CD8+ T cells in promoting IL-10 
production remain to be determined. Nevertheless, type I IFN signaling substantially 
enhances IL-10 by CD8+ T cells in vitro in the presence of IL-2 and IL-27. At present, the 
mechanism(s) by which type I IFNs co-operate with IL-2 and IL-27 to promote IL-10 
production is unknown. Type I IFN signaling has been shown to sustain the expression of 
high affinity IL-2 receptor on CD8+ T cell surface (43). So it is possible that type I IFN 
signaling promotes IL-10 production by facilitating IL-2 and/or IL-27 signaling in CD8+ T 
cells. Conversely, it is possible that IL-2 and IL-27 treatment could boost IFNAR1 
expression and/or its downstream signaling to promote IL-10 expression.
Mechanistically, we found that type I IFN signaling promotes of IL-10 production through 
the concerted action of STAT2, IRF4 and Blimp-1. In a previous report we identified IRF4 
expression as essential for the induction of Blimp-1 and its downstream anti-viral effector 
cytokine molecules in CD8+ T cells (29). By normalizing IL-10-producing cells to IFN-γ 
producing cells, we showed that IRF4 is also critically important for IL-10 production by 
CD8+ T cells. We speculate that IRF4 functions upstream of Blimp-1 to promote IL-10 
expression in CD8+ T cells. However it is also possible that IRF4 could directly bind to the 
IL-10 locus to promote IL-10 production in CD8+ T cells since it was shown that the IL-10 
locus contains IRF4 binding motifs (30). The strength of TCR signaling (i.e. high antigen 
dose and strong peptide affinity) was also shown to be critical for IRF4 expression in CD8+ 
T cells. Here we have extended previous findings by demonstrating that IRF4 expression is 
also modulated by cytokine signaling (i.e. type I IFNs). Of note, high dose antigen 
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stimulation has been shown to favor IL-10 production by CD4 T cells (44). We have shown 
previously that IL-10 production by CD8+ T cells was highly restricted to the early time 
frame following virus specific T cell infiltration to the lungs during influenza infection (8), 
at the time when virus-derived antigens are plentiful in the infected lungs. Thus it is possible 
that both TCR-derived signaling and type I IFNs derived signaling are required for the 
optimal induction of IRF4 and downstream IL-10 production in vivo. These possibilities 
warrant further investigations.
In summary, our data have revealed potential regulatory roles of type I IFN signaling in 
inflammatory responses during acute viral infections, and may provide the groundwork for 
manipulating IL-10 production in effector CD8+ T cells to control excessive host 
inflammation during acute respiratory virus infection.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Type I IFN signaling is required for the optimal induction of IL-10-producing effector 
CD8+ T cells
(A–F) WT or Ifnar1−/− mice (n = 3) were infected with influenza. IL-10 production by lung 
T cells and IL-10 levels in the airway were determined at day 7 post infection.
(A). Production of IL-10 and IFN-γ by lung CD8+ T cells from WT or Ifnar1−/− mice 
following in vitro antigenic stimulation with influenza-infected WT BMDCs.
(B). Normalized percentages of IL-10+ cells in influenza-specific lung CD8+ T cells (IFN-
γ+) from infected WT or Ifnar1−/− mice.
(C). Production of IL-10 and IFN-γ by lung CD4+ T cells following in vitro antigenic 
stimulation with influenza-infected WT BMDCs.
(D). Normalized percentages of IL-10+ cells in influenza-specific lung CD4+ T cells (IFN-
γ+) from infected WT or Ifnar1−/− mice.
(E). IL-10 levels in the BALF from WT or Ifnar1−/− mice were determined through ELISA.
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(F). IFN-γ levels in the BALF from WT or Ifnar1−/− mice were determined through ELISA.
(G). Production of IL-10 and IFN-γ by lung CD8+ T cells from WT or Stat2−/− mice (n = 2 
– 3) following in vitro antigenic stimulation with influenza-infected WT BMDCs.
(H). Normalized percentages of IL-10+ cells in influenza-specific lung CD8+ T cells (IFN-
γ+) from infected WT or Stat2−/− mice.
Data are representative of two to four separate experiments. Statistics were determined by 
unpaired two-tailed Student’s t-test, *P < 0.05.
Jiang et al. Page 14
Eur J Immunol. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. Type I IFN signaling is required for the optimal in vivo expression of IL-10 by CD8+ T 
cells
Vert-X or Ifnar1−/− Vert-X mice (n = 3 – 4) were infected with influenza. IL-10 expression 
by T cells in vivo was measured through their eGFP expression by flow cytometry at day 7 
p.i.
(A). Expression of IL-10-eGFP by total lung CD8+ T cells from infected Vert-X or Ifnar1−/− 
Vert-X mice.
(B). Percentages IL-10-eGFP+ of cells in total lung CD8+ T cells from infected Vert-X or 
Ifnar1−/− Vert-X mice.
(C). IL-10-eGFP expression levels (MFI) of the IL-10-eGFP+ of cells in total lung CD8+ T 
cells from infected Vert-X or Ifnar1−/− Vert-X mice.
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(D). Expression of IL-10-eGFP by influenza-specific PA224+ lung CD8+ T cells from 
infected Vert-X or Ifnar1−/− Vert-X mice.
(E). Percentages IL-10-eGFP+ of cells in influenza-specific PA224+ lung CD8+ T cells from 
infected Vert-X or Ifnar1−/− Vert-X mice.
(F). IL-10-eGFP expression levels (MFI) of the IL-10-eGFP+ of cells in influenza-specific 
PA224+ lung CD8+ T cells from infected Vert-X or Ifnar1−/− Vert-X mice.
(G). Expression of IL-10-eGFP by total lung CD4+ T cells from infected Vert-X or Ifnar1−/− 
Vert-X mice.
(H). Percentages IL-10-eGFP+ of cells in total lung CD4+ T cells from infected Vert-X or 
Ifnar1−/− Vert-X mice.
Data are representative of at least three separate experiments. Statistics were determined by 
unpaired two-tailed Student’s t-test, *P < 0.05. n.s., non-significant.
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Figure 3. Type I IFN signaling is required for optimal IL-27 expression during influenza 
infection
WT mice were infected with influenza. IL-27 subunit (Ebi3 and p28) gene expression in 
different lung cells populations (A), mediastinal lymph nodes (MLN) and lungs (B) as well 
as p28 protein production in the airway (C) were determined at day 5 p.i.
(A). Ebi3 and p28 gene expression in various cell types sorted from the lungs of WT mice 
(pooled from 2 – 3 mice) at day 5 p.i.
(B) Ebi3 and p28 gene expression in the lung and draining MLN from WT or Ifnar1−/− mice 
(n=2 – 4) was determined through real-time RT-PCR.
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(C). p28 protein levels in the BALF from WT or Ifnar1−/− mice (n = 2 – 4) were determined 
through ELISA.
Data are representative of two separate experiments. Statistics were determined by unpaired 
two-tailed Student’s t-test, *P < 0.05.
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Figure 4. Direct type I IFN signaling in CD8+ T cells is required for optimal IL-10 production by 
effector CD8+ T cells
WT and Ifnar1−/− mixed bone marrow chimera mice (n= 5) were infected with influenza. 
IL-10 production by lung T cells was determined at day 7 post infection following 
stimulation with influenza-infected WT BMDCs.
(A). Schematics of the construction of BM chimeric mice.
(B). Production of IL-10 and IFN-γ by WT or Ifnar1−/− lung CD8+ T cells following in vitro 
antigenic stimulation with influenza-infected WT BMDCs.
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(C). Normalized percentages of IL-10+ cells in influenza-specific WT or Ifnar1−/− lung 
CD8+ T cells.
(D). IL-10 levels (MFI) produced by WT or Ifnar1−/− lung CD8+ T cells following in vitro 
antigenic stimulation with influenza-infected WT BMDCs.
(E). Normalized percentages of IL-10+ cells in influenza-specific WT or Ifnar1−/− lung 
CD4+ T cells (IFN-γ+) from infected WT and Ifnar1−/− mice.
Data are representative of two separate experiments. Statistics were determined by paired 
two-tailed Student’s t-test, *P < 0.05.
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Figure 5. Type I IFNs further promote IL-10 production by CD8+ T cells in the presence of IL-2 
plus IL-27
(A) Production of IL-10 by CD8+ T cells following in vitro culture with indicated conditions 
(no cytokines, IFN-α, IL-2 plus IL-27 or IFN-α plus IL-2 and IL-27).
(B) Percentages of IL-10-producing CD8+ T cells following in vitro culture with indicated 
conditions (IL-2 plus IL-27 or IFN-α plus IL-2 and IL-27) in total of 4 experiments.
(C) IL-10 gene expression in CD8+ T cells following in vitro culture with indicated 
conditions (no cytokines, IFN-α, IL-2 plus IL-27 or IFN-α plus IL-2 and IL-27).
(D) IL-10 protein production in the supernatants following αCD3 restimulation of CD8+ T 
cells cultured with indicated conditions (no cytokines, IFN-α, IL-2 plus IL-27 or IFN-α plus 
IL-2 and IL-27).
Data are representative of three to four separate experiments. Statistics were determined by 
paired two-tailed Student’s t-test, *P < 0.05.
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Figure 6. Blimp-1 and IRF4 are required for the development of IL-10-producing effector CD8+ 
T cells induced by type I IFNs plus IL-2 and IL-27
(A) Prdm1 (Blimp-1 gene) expression in CD8+ T cells following in vitro culture with 
indicated conditions (no cytokines, IFN-α, IL-2 plus IL-27 or IFN-α plus IL-2 and IL-27).
(B) Prdm1 expression in CD8+ T cells following in vitro culture with indicated conditions 
(IL-2 plus IL-27 or IFN-α plus IL-2 and IL-27) in total of three experiments.
(C) Production of IL-10 by control or Blimp-1 cKO CD8+ T cells following in vitro culture 
with indicated conditions (no cytokines, IFN-α, IL-2 plus IL-27 or IFN-α plus IL-2 and 
IL-27).
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(D) IL-10 protein production in the supernatants following restimulation of control or 
Blimp-1 cKO CD8+ T cells cultured with indicated conditions (no cytokines, IFN-α, IL-2 
plus IL-27 or IFN-α plus IL-2 and IL-27).
(E) IRF4 expression in CD8+ T cells cultured with indicated conditions (no cytokines, IFN-
α, IL-2 plus IL-27 or IFN-α plus IL-2 and IL-27).
(F) Production of IL-10 by control or IRF4 cKO CD8+ T cells following in vitro culture with 
indicated conditions (no cytokines, IFN-α, IL-2 plus IL-27 or IFN-α plus IL-2 and IL-27).
(G) IL-10 protein production in the supernatants following restimulation of WT or IRF4 
cKO CD8+ T cells cultured with indicated conditions (no cytokines, IFN-α, IL-2 plus IL-27 
or IFN-α plus IL-2 and IL-27).
(H) Production of IL-10 and IFN-γ by lung CD8+ T cells from WT or IRF4 cKO mice (n= 2 
– 3) following in vitro antigenic stimulation with influenza-infected WT BMDCs.
(I). Normalized percentages of IL-10+ cells in influenza-specific lung CD8+ T cells (IFN-
γ+) from infected control or IRF4 cKO mice.
(J). Model of type I IFN-dependent IL-10 production by CD8+ T cells.
Data are representative of at least two separate experiments. Statistics were determined by 
paired (B) or unpaired (I) two-tailed Student’s t-test, *P < 0.05.
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